Thermal ablation vs. conventional neck dissection for recurrent low-burden lymph node metastasis in thyroid cancer: a dual-center retrospective cohort study.
OpenAlex 토픽 ·
Thyroid and Parathyroid Surgery
Thyroid Cancer Diagnosis and Treatment
Management of metastatic bone disease
[OBJECTIVE] To compare ultrasound-guided thermal ablation (TA) with conventional neck dissection (CND) for recurrent low-burden lymph node metastasis (≤3 lesions, <2 cm) in regional recurrences of thy
APA
Xiaojian Ye, Lei Yan, et al. (2026). Thermal ablation vs. conventional neck dissection for recurrent low-burden lymph node metastasis in thyroid cancer: a dual-center retrospective cohort study.. International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 43(1), 2602514. https://doi.org/10.1080/02656736.2025.2602514
MLA
Xiaojian Ye, et al.. "Thermal ablation vs. conventional neck dissection for recurrent low-burden lymph node metastasis in thyroid cancer: a dual-center retrospective cohort study.." International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, vol. 43, no. 1, 2026, pp. 2602514.
PMID
41883104
Abstract
[OBJECTIVE] To compare ultrasound-guided thermal ablation (TA) with conventional neck dissection (CND) for recurrent low-burden lymph node metastasis (≤3 lesions, <2 cm) in regional recurrences of thyroid papillary carcinoma, and to guide risk-adaptive therapeutic strategies.
[METHODS] A dual-center retrospective study (2016-2022) analyzed 230 patients with recurrent lymph node metastasis, stratified into TA ( = 115) and reoperation groups ( = 115). Endpoints included recurrence-free survival, complications, thyroglobulin (Tg) dynamics, quality of life (EORTC QLQ-C30), and healthcare costs.
[RESULTS] Oncological Outcomes: No significant difference in 36-month recurrence rates (Log-rank = 0.54; Bonferroni-corrected = 1.00).Safety: Similar complication rates (nerve injury, hypocalcemia, hematoma, infection; all > 0.7).TA Advantages: Shorter operative time, less blood loss, faster recovery, shorter hospital stays, and lower costs. Nearly 50% of TA-treated patients achieved complete lymph node volume reduction (100% VRR) within 36 months.
[CONCLUSION] TA demonstrates non-inferior oncological efficacy compared to CND for strictly selected patients with recurrent low-burden lymph node metastasis, offering minimally invasive, risk-adaptive therapeutic strategies with superior procedural efficiency and quality-of-life benefits.
[METHODS] A dual-center retrospective study (2016-2022) analyzed 230 patients with recurrent lymph node metastasis, stratified into TA ( = 115) and reoperation groups ( = 115). Endpoints included recurrence-free survival, complications, thyroglobulin (Tg) dynamics, quality of life (EORTC QLQ-C30), and healthcare costs.
[RESULTS] Oncological Outcomes: No significant difference in 36-month recurrence rates (Log-rank = 0.54; Bonferroni-corrected = 1.00).Safety: Similar complication rates (nerve injury, hypocalcemia, hematoma, infection; all > 0.7).TA Advantages: Shorter operative time, less blood loss, faster recovery, shorter hospital stays, and lower costs. Nearly 50% of TA-treated patients achieved complete lymph node volume reduction (100% VRR) within 36 months.
[CONCLUSION] TA demonstrates non-inferior oncological efficacy compared to CND for strictly selected patients with recurrent low-burden lymph node metastasis, offering minimally invasive, risk-adaptive therapeutic strategies with superior procedural efficiency and quality-of-life benefits.
MeSH Terms
Humans; Female; Male; Retrospective Studies; Thyroid Neoplasms; Lymphatic Metastasis; Middle Aged; Neck Dissection; Adult; Aged; Ablation Techniques
같은 제1저자의 인용 많은 논문 (5)
- Prognostic Significance of Different Ki-67 Cutoff Values Defined Luminal B HER2-Negative Breast Cancer.
- Systemic serum protein alterations and molecular mechanisms in alcohol dependence.
- Asia's accelerating burden of early-onset pancreatic cancer: a 32-year global comparative analysis using GBD 2021.
- Emerging Claudin18.2-targeting Therapy for Systemic Treatment of Gastric Cancer: Seeking Nobility Amidst Danger.
- Knockdown of TBRG4 suppresses the migration, invasion, and epithelial-to-mesenchymal transition of pancreatic cancer cells via TGF-β/smad3 signaling.